行情

BMY

BMY

百时美施贵宝
NYSE

实时行情|Nasdaq Last Sale

64.16
-2.71
-4.05%
盘后: 64.17 +0.01 +0.02% 19:31 01/24 EST
开盘
66.39
昨收
66.87
最高
66.74
最低
63.61
成交量
2,245.30万
成交额
--
52周最高
68.34
52周最低
42.48
市值
1,504.04亿
市盈率(TTM)
18.54
分时
5日
1月
3月
1年
5年

分析师评级

14位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BMY 新闻

  • 苹果与博通签订两份合作协议 后者有望赚150亿美元
  • 新浪科技.6小时前
  • 蛋壳公寓将为武汉医护人员提供专属免费住房
  • 新浪科技.6小时前
  • 亚澳美欧11国超30例确诊感染 多国计划从武汉撤侨
  • 界面.6小时前
  • 红杉中国致信成员企业:坚定信心、砥砺前行
  • 新浪财经.8小时前

更多

所属板块

制药
-1.84%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

BMY 简况

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company's pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics. Small molecule drugs are administered orally in the form of a pill or tablet. Biologics are administered to patients through injections or by infusion. The Company's products include Empliciti, Opdivo, Sprycel, Yervoy, Eliquis, Orencia, Baraclude, Hepatitis C Franchise, Reyataz Franchise and Sustiva Franchise. It offers products for a range of therapeutic classes, which include virology, including human immunodeficiency virus (HIV) infection; oncology; immunoscience, and cardiovascular. Its products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession across the world. The Company’s subsidiary is Celgene Corp.
展开

Webull提供Bristol-Myers Squibb Co的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。